JP2022537515A - 抗体－インターロイキン融合タンパク質および使用方法 - Google Patents

抗体－インターロイキン融合タンパク質および使用方法 Download PDF

Info

Publication number
JP2022537515A
JP2022537515A JP2021573591A JP2021573591A JP2022537515A JP 2022537515 A JP2022537515 A JP 2022537515A JP 2021573591 A JP2021573591 A JP 2021573591A JP 2021573591 A JP2021573591 A JP 2021573591A JP 2022537515 A JP2022537515 A JP 2022537515A
Authority
JP
Japan
Prior art keywords
antibody
protein
antigen
disease
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537515A5 (https=
JPWO2020249003A5 (https=
Inventor
ヤン，ラン
ユ，グオリャン
シ，キアン
フェイ，ゾンウェイ
マ，ビャオ
Original Assignee
アポロミクス インコーポレイテッド（ハンジョウ）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アポロミクス インコーポレイテッド（ハンジョウ） filed Critical アポロミクス インコーポレイテッド（ハンジョウ）
Publication of JP2022537515A publication Critical patent/JP2022537515A/ja
Publication of JP2022537515A5 publication Critical patent/JP2022537515A5/ja
Publication of JPWO2020249003A5 publication Critical patent/JPWO2020249003A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021573591A 2019-06-10 2020-06-10 抗体－インターロイキン融合タンパク質および使用方法 Pending JP2022537515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/090494 2019-06-10
CN2019090494 2019-06-10
PCT/CN2020/095354 WO2020249003A1 (en) 2019-06-10 2020-06-10 Antibody-interleukin fusion protein and methods of use

Publications (3)

Publication Number Publication Date
JP2022537515A true JP2022537515A (ja) 2022-08-26
JP2022537515A5 JP2022537515A5 (https=) 2023-06-19
JPWO2020249003A5 JPWO2020249003A5 (https=) 2023-06-19

Family

ID=73781610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573591A Pending JP2022537515A (ja) 2019-06-10 2020-06-10 抗体－インターロイキン融合タンパク質および使用方法

Country Status (6)

Country Link
US (1) US20220306713A1 (https=)
EP (1) EP3980067A4 (https=)
JP (1) JP2022537515A (https=)
CN (1) CN114599390A (https=)
CA (1) CA3143218A1 (https=)
WO (1) WO2020249003A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126965A4 (en) * 2020-05-14 2024-10-02 Elixiron Immunotherapeutics (Hong Kong) Limited ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
CN118434759A (zh) * 2021-10-10 2024-08-02 安立玺荣生医(香港)有限公司 用抗-pd-l1/il-10融合蛋白治疗疾病的方法
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
CN116063547A (zh) * 2022-07-08 2023-05-05 盛禾(中国)生物制药有限公司 一种二聚体融合蛋白及其应用
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2025077212A1 (zh) * 2023-10-08 2025-04-17 广东菲鹏制药股份有限公司 抗pd1-il10融合蛋白及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523786A (ja) * 2014-08-05 2017-08-24 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2017530722A (ja) * 2014-07-22 2017-10-19 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−１抗体
JP2019510478A (ja) * 2016-02-05 2019-04-18 オリオニス バイオサイエンシズ エヌブイ 標的療法剤およびその使用
WO2019094268A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592420A (en) * 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
EP3068425B1 (en) * 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017530722A (ja) * 2014-07-22 2017-10-19 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−１抗体
JP2017523786A (ja) * 2014-08-05 2017-08-24 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2019510478A (ja) * 2016-02-05 2019-04-18 オリオニス バイオサイエンシズ エヌブイ 標的療法剤およびその使用
WO2019094268A1 (en) * 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H.ZHANG, ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 29, JPN6024024496, 2016, pages 3576 - 3578, ISSN: 0005485504 *

Also Published As

Publication number Publication date
CA3143218A1 (en) 2020-12-17
CN114599390A (zh) 2022-06-07
EP3980067A4 (en) 2023-08-02
EP3980067A1 (en) 2022-04-13
US20220306713A1 (en) 2022-09-29
WO2020249003A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CN110050000B (zh) 含有TGF-β受体的融合蛋白及其医药用途
JP2022537515A (ja) 抗体－インターロイキン融合タンパク質および使用方法
Strohl Current progress in innovative engineered antibodies
US12325742B2 (en) Anti-mesothelin antibodies
JP2023126951A (ja) Ｃｄ１３７に結合するシングルドメイン抗体
TWI840433B (zh) 新穎合理設計的蛋白質組合物
EP3936526A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
CN108463245A (zh) 具有修饰的j链的结合分子
CN111727057A (zh) 与lag3和pd1结合的治疗分子
US12590149B2 (en) Antibody and bispecific antibody targeting LAG-3 and use thereof
US12428479B2 (en) CLDN18.2-targeting antibody, bispecific antibody and use thereof
CN117024592B (zh) 抗b7h3抗体及其用途
WO2022002038A1 (zh) 免疫细胞衔接器多特异性结合蛋白及其制备和应用
EP4389770A1 (en) Bispecific antibody and use thereof
WO2023011654A1 (zh) 抗pd-1纳米抗体及其应用
CN114790241B (zh) 抗tigit抗体及其应用
EP4023679A1 (en) Fusion protein targeting pd-l1 and tgf-beta and use thereof
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
KR20240127523A (ko) 항-cntn4 항체 및 그의 용도
WO2022228431A1 (zh) 抗pd-l1单域抗体及其用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
WO2026085716A1 (zh) 新型il-18替代物及其用途
JP2025530110A (ja) 二重特異性ポリペプチド及びその使用
CN121591904A (zh) 靶向Trop2和HER2的双特异性抗体及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241217